Container Performance Testing - New Proposal for USP General Chapter <671>
Recommendation

20/21 October 2026
Performance Evaluation and Monitoring for compliant Analytical Procedures and Processes
In Pharmacopoeial Forum 39 (2) a proposal for the revision of USP General Chapter <671> was published. According to the summary of this change package integrity is necessary to maintain the drug product's quality throughout its shelf life. Packaging systems have to demonstrate satisfactory container-closure integrity. It is proposed that this chapter will be revised to include a new permeation method for determining barrier protection for packaging systems.
The purpose of this chapter is to provide standards for the functional properties of packaging systems used for solid oral dosage forms and liquid dosage forms for pharmaceuticals. Test methods are provided to measure moisture vapour transmission rates that are useful for pharmaceutical manufacturers to determine the level of barrier protection provided by packaging systems. Additional methods are provided to determine classification of packaging systems.
Definitions and moisture vapour transmission rates at 40°/75% relative humidity (RH)are given for the following blisters:
- Low-barrier blister - greater than 1.0 mg/cavity-day
- High-barrier blister - less than 1.0 mg/cavity-day
- Ultra-high barrier blister - less than 0.01 mg/cavity-day
Other methods may be used, if these alternative methods are described in sufficient detail to
justify their use.
More information can be found in the USP's Pharmacopeial Forum (PF).
Source: USP
Related GMP News
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination
30.09.2026The Relationship between the BP and the Ph. Eur.
30.09.2026New Japanese Pharmacopoeia Drafts (September 2026) Open for Public Comment
30.09.2026EMA publishes final ICH M13B Guideline and Q&A on Bioequivalence

